Precigen, Inc. (NASDAQ:PGEN) Given Average Rating of “Hold” by Analysts

Precigen, Inc. (NASDAQ:PGEN) has been given a consensus recommendation of “Hold” by the six analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $12.50.

Several equities analysts have weighed in on PGEN shares. Citizens Jmp lifted their price objective on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a report on Thursday, May 14th. HC Wainwright increased their target price on Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Tuesday, April 21st. Wall Street Zen downgraded Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Finally, Citigroup reaffirmed an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th.

Precigen Stock Performance

NASDAQ PGEN opened at $5.53 on Friday. The firm has a 50-day moving average of $4.61 and a 200-day moving average of $4.29. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. The stock has a market cap of $1.97 billion, a PE ratio of -4.69 and a beta of 1.00. Precigen has a 52-week low of $1.47 and a 52-week high of $6.04.

Precigen (NASDAQ:PGEN) last announced its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The company had revenue of $23.25 million for the quarter, compared to analyst estimates of $20.81 million. On average, sell-side analysts anticipate that Precigen will post -0.02 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Helen Sabzevari sold 346,836 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the sale, the chief executive officer owned 3,768,872 shares in the company, valued at $22,198,656.08. The trade was a 8.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Rutul R. Shah sold 42,924 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.85, for a total value of $251,105.40. Following the sale, the chief operating officer owned 497,751 shares in the company, valued at approximately $2,911,843.35. This trade represents a 7.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 822,728 shares of company stock valued at $4,422,853. 41.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Precigen

A number of hedge funds have recently made changes to their positions in PGEN. Xponance LLC raised its holdings in Precigen by 21.3% during the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,496 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 2,993 shares during the last quarter. Composition Wealth LLC increased its position in shares of Precigen by 16.5% during the fourth quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock worth $89,000 after buying an additional 3,000 shares during the period. Intech Investment Management LLC increased its position in shares of Precigen by 5.2% during the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock worth $263,000 after buying an additional 3,137 shares during the period. Finally, Cetera Investment Advisers raised its stake in Precigen by 0.9% during the first quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock worth $1,449,000 after buying an additional 3,250 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.